These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17031376)

  • 1. Testosterone levels in benign prostatic hyperplasia: sexual function and response to therapy with dutasteride.
    Swerdloff R
    Nat Clin Pract Urol; 2006 Oct; 3(10):528-9. PubMed ID: 17031376
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
    Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options for patients with benign prostatic hyperplasia.
    Ellenberger B
    CMAJ; 1993 Feb; 148(4):543-7. PubMed ID: 7679313
    [No Abstract]   [Full Text] [Related]  

  • 7. Finasteride for benign prostatic hyperplasia.
    DuBeau CE
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678439
    [No Abstract]   [Full Text] [Related]  

  • 8. Dutasteride (Avodart): new 5-alpha-reductase inhibitor for treating BPH.
    Gaines KK
    Urol Nurs; 2003 Jun; 23(3):218-20. PubMed ID: 12861740
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
    Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finasteride for benign prostatic hyperplasia.
    Blumenstein BA
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678438
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].
    Grigor'ev ME; Konorev VA
    Urologiia; 2007; (6):90, 92-5. PubMed ID: 18652016
    [No Abstract]   [Full Text] [Related]  

  • 14. Dutasteride (Avodart) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2002 Dec; 44(1146):109-10. PubMed ID: 12500154
    [No Abstract]   [Full Text] [Related]  

  • 15. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dutasteride (Avodart): a novel 5-alpha reductase inhibitor for treatment of benign prostate hypertrophy].
    Vanden Bossche M; Sternon J
    Rev Med Brux; 2005; 26(2):103-6. PubMed ID: 15945422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urination disorders, endocrine features and sexual activity in patients with benign prostatic hypertrophy under treatment with mepartricin].
    Scarpa RM; Migliari R; De Lisa A; Campus G; Usai E
    Minerva Urol Nefrol; 1988; 40(2 Suppl):18-20. PubMed ID: 2460939
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].
    Tsukamoto T; Endo Y; Narita M
    Hinyokika Kiyo; 2009 Apr; 55(4):209-14. PubMed ID: 19462826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.